XML 32 R19.htm IDEA: XBRL DOCUMENT
v3.7.0.1

13. Restructuring Costs (Notes) | 3 Months Ended
--- | ---
Mar. 31, 2017
Restructuring Costs [Abstract] |
Restructuring and Related Activities Disclosure [Text Block] | 13. RESTRUCTURING COSTS For the three months ended March 31, 2017, we recorded less than $0.1 million related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams. The following table summarizes the activity of our restructuring reserves for severance (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Total
Balance at December 31, 2016 |  | $ | 3.2 |  |  | $ | 5.8 |  |  | $ | 9.0 |
Charged to expense |  | — |  |  | — |  |  | — |
Adjustment to expense |  | — |  |  | — |  |  | — |
Cash payments |  | (0.3 | ) |  | (0.6 | ) |  | (0.9 | )
Foreign currency translation losses |  | — |  |  | 0.1 |  |  | 0.1 |
Balance at March 31, 2017 |  | $ | 2.9 |  |  | $ | 5.3 |  |  | $ | 8.2 |
In May, 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three months ended March 31, 2017. The liability of $8.2 million as of March 31, 2017 encompassed a short-term liability of $5.8 million and a long-term liability of $2.4 million, and is anticipated to be paid through 2019. The amounts recorded were reflected in Cost of goods sold of $(0.1) million and in Selling, general and administrative expense of $0.1 million in the Condensed Consolidated Statements of Income for the three months ended March 31, 2017. The amounts adjusted were primarily due to employees finding other positions within Bio-Rad or leaving prematurely.

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RestructuringCostsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration